MedTrace Logo

Peripheral Vascular REactivity and Muscular Oxygenation in Diabetes Mellitus

NCT04226820 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2023-11-30

No results posted yet for this study

Summary

Oxygen is required for an optimal muscle function. In patients with diabetes mellitus, hyperglycemia can cause vascular complications. The endothelium (inter layer of the blood vessels) can be damaged leading to a reduced oxygen flow towards the muscle cells. Besides, it is possible that mitochondrial dysfunction is occuring leading to reduced extraction of oxygen.

Both conditions will lead to a reduced flow of oxygen towards the muscle and this can have impact on the production of energy necessary for optimal functioning.

In this study, the investigators will examine the functionality of the blood vessels (1) and the uptake of oxygen into the muscles (2) in patients with diabetes mellitus type 1 and type 2 (with and without vascular complications) compared to healthy persons.

Conditions

Interventions

OTHER

examination: blood pressure assessment

blood pressure measurement for 30 minutes, dominant side

OTHER

examination: Flow Mediated Dilatation (FMD)-test

Flow Mediated Dilatation (FMD)-test for measuring the endothelial functionality

OTHER

examination: handgrip exercise test with Near infrared spectroscopy (NIRS)-monitoring

participant does a maximal exercise test by a handgrip strength test with simultaneously monitoring of the muscular oxygenation

OTHER

examination: measurement of glucose by a finger prick

follow-up of blood sugar (glucose) during examinations by a finger prick

Sponsors & Collaborators

  • University Hospital, Ghent

    collaborator OTHER

  • University Ghent

    lead OTHER

Principal Investigators

  • Samyah Shadid, Prof. dr. · University hospital of Ghent and University of Ghent

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2024-10-31
Completion
2024-10-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04226820 on ClinicalTrials.gov